EWM
ALXN

Executive Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Executive Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-44
Closed -$6K – 893
2019
Q2 		$6K Hold
44
– – ﹤0.01% 700
2019
Q1 		$6K Sell
44
-10
-19% -$1.24K ﹤0.01% 633
2018
Q4 		$5K Buy
+54
New +$6.38K ﹤0.01% 691

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Executive Wealth Management's ALXN Position: Q3 2019 in Review

Executive Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 44 shares — an estimated $6K sold.

Executive Wealth Management first reported a position in ALXN in Q4 2018 and held it in 3 quarters. The position peaked at $6K in Q2 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Executive Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 44 Alexion Pharmaceuticals shares in Q3 2019, an estimated $6K.
  • Executive Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Executive Wealth Management's Alexion Pharmaceuticals position peaked at $6K in Q2 2019.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.